H. Lundbeck A/s

This study is testing whether an intravenous medication called eptinezumab can reduce the number of migraine days in teenagers aged 12-17 who have chronic migraines. Participants receive a single IV infusion and are followed for 20 weeks to see if the treatment works better than …

This early-stage trial is testing a new drug called Lu AG13909 in adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that affects hormone production. The main goals are to check the drug's safety, see how it moves through the body, and measure its effect o…

This study aims to check the long-term safety of eptinezumab, a medication given by infusion, in children and teens aged 6 to 17 who have chronic or episodic migraine. It is an extension for participants who completed a previous 12-week study. The main goal is to monitor for any …

This study is testing whether a medication called eptinezumab, given through an IV, can safely reduce the number of migraine days for children and teenagers aged 6 to 17. It is a large, late-stage trial comparing the drug to a placebo. The main goal is to see if the treatment hel…

This study is testing an investigational drug called Lu AG13909 in adults with Cushing's disease, a rare disorder where the body makes too much of the stress hormone cortisol. The main goals are to see if the drug can safely lower cortisol levels and how the body processes it. Th…